{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,13]],"date-time":"2026-10-13T20:52:39Z","timestamp":1791924759840,"version":"4.3.4"},"reference-count":152,"publisher":"Springer Science and Business Media LLC","issue":"9","license":[{"start":{"date-parts":[[2024,8,9]],"date-time":"2024-08-09T00:00:00Z","timestamp":1723161600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2024,8,9]],"date-time":"2024-08-09T00:00:00Z","timestamp":1723161600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Nat Rev Neurol"],"published-print":{"date-parts":[[2024,9]]},"DOI":"10.1038\/s41582-024-01001-6","type":"journal-article","created":{"date-parts":[[2024,8,9]],"date-time":"2024-08-09T08:01:50Z","timestamp":1723190510000},"page":"509-525","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":50,"title":["Peripheral nervous system immune-related adverse events due to checkpoint inhibition"],"prefix":"10.1038","volume":"20","author":[{"ORCID":"https:\/\/orcid.org\/0009-0004-7537-7803","authenticated-orcid":false,"given":"Meabh","family":"O\u2019Hare","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Amanda C.","family":"Guidon","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2024,8,9]]},"reference":[{"key":"1001_CR1","doi-asserted-by":"publisher","first-page":"158","DOI":"10.1056\/NEJMra1703481","volume":"378","author":"MA Postow","year":"2018","unstructured":"Postow, M. A., Sidlow, R. & Hellmann, M. D. Immune-related adverse events associated with immune checkpoint blockade. N. Engl. J. Med. 378, 158\u2013168 (2018).","journal-title":"N. Engl. J. Med."},{"key":"1001_CR2","doi-asserted-by":"publisher","first-page":"1575","DOI":"10.1016\/j.cell.2021.02.011","volume":"184","author":"M Dougan","year":"2021","unstructured":"Dougan, M., Luoma, A. M., Dougan, S. K. & Wucherpfennig, K. W. Understanding and treating the inflammatory adverse events of cancer immunotherapy. Cell 184, 1575\u20131588 (2021).","journal-title":"Cell"},{"key":"1001_CR3","doi-asserted-by":"publisher","first-page":"1069","DOI":"10.1158\/2159-8290.CD-18-0367","volume":"8","author":"SC Wei","year":"2018","unstructured":"Wei, S. C., Duffy, C. R. & Allison, J. P. Fundamental mechanisms of immune checkpoint blockade therapy. Cancer Discov. 8, 1069\u20131086 (2018).","journal-title":"Cancer Discov."},{"key":"1001_CR4","doi-asserted-by":"publisher","first-page":"492","DOI":"10.1038\/ni.2035","volume":"12","author":"EJ Wherry","year":"2011","unstructured":"Wherry, E. J. T cell exhaustion. Nat. Immunol. 12, 492\u2013499 (2011).","journal-title":"Nat. Immunol."},{"key":"1001_CR5","doi-asserted-by":"publisher","first-page":"1767","DOI":"10.1056\/NEJMra1514296","volume":"375","author":"VA Boussiotis","year":"2016","unstructured":"Boussiotis, V. A. Molecular and biochemical aspects of the PD-1 checkpoint pathway. N. Engl. J. Med. 375, 1767\u20131778 (2016).","journal-title":"N. Engl. J. Med."},{"key":"1001_CR6","doi-asserted-by":"publisher","first-page":"576","DOI":"10.1016\/j.cell.2022.01.008","volume":"185","author":"G Morad","year":"2022","unstructured":"Morad, G., Helmink, B. A., Sharma, P. & Wargo, J. A. Hallmarks of response, resistance, and toxicity to immune checkpoint blockade. Cell 185, 576 (2022).","journal-title":"Cell"},{"key":"1001_CR7","doi-asserted-by":"publisher","DOI":"10.1136\/jitc-2020-001014","volume":"8","author":"T Maruhashi","year":"2020","unstructured":"Maruhashi, T., Sugiura, D., Okazaki, I. & Okazaki, T. LAG-3: from molecular functions to clinical applications. J. Immunother. Cancer 8, e001014 (2020).","journal-title":"J. Immunother. Cancer"},{"key":"1001_CR8","doi-asserted-by":"publisher","first-page":"563","DOI":"10.1038\/s41571-019-0218-0","volume":"16","author":"F Martins","year":"2019","unstructured":"Martins, F. et al. Adverse effects of immune-checkpoint inhibitors: epidemiology, management and surveillance. Nat. Rev. Clin. Oncol. 16, 563\u2013580 (2019).","journal-title":"Nat. Rev. Clin. Oncol."},{"key":"1001_CR9","doi-asserted-by":"publisher","first-page":"98","DOI":"10.1097\/COC.0000000000000239","volume":"39","author":"EI Buchbinder","year":"2016","unstructured":"Buchbinder, E. I. & Desai, A. CTLA-4 and PD-1 pathways: similarities, differences, and implications of their inhibition. Am. J. Clin. Oncol. 39, 98\u2013106 (2016).","journal-title":"Am. J. Clin. Oncol."},{"key":"1001_CR10","doi-asserted-by":"publisher","first-page":"24","DOI":"10.1056\/NEJMoa2109970","volume":"386","author":"HA Tawbi","year":"2022","unstructured":"Tawbi, H. A. et al. Relatlimab and nivolumab versus nivolumab in untreated advanced melanoma. N. Engl. J. Med. 386, 24\u201334 (2022).","journal-title":"N. Engl. J. Med."},{"key":"1001_CR11","doi-asserted-by":"publisher","first-page":"134","DOI":"10.1186\/s40425-019-0617-x","volume":"7","author":"DB Johnson","year":"2019","unstructured":"Johnson, D. B. et al. Neurologic toxicity associated with immune checkpoint inhibitors: a pharmacovigilance study. J. Immunother. Cancer 7, 134 (2019).","journal-title":"J. Immunother. Cancer"},{"key":"1001_CR12","doi-asserted-by":"publisher","first-page":"38","DOI":"10.1038\/s41572-020-0160-6","volume":"6","author":"M Ramos-Casals","year":"2020","unstructured":"Ramos-Casals, M. et al. Immune-related adverse events of checkpoint inhibitors. Nat. Rev. Dis. Prim. 6, 38 (2020).","journal-title":"Nat. Rev. Dis. Prim."},{"key":"1001_CR13","doi-asserted-by":"publisher","first-page":"514","DOI":"10.1002\/onco.13740","volume":"26","author":"GE Molina","year":"2021","unstructured":"Molina, G. E. et al. Temporal trends and outcomes among patients admitted for immune\u2010related adverse events: a single\u2010center retrospective cohort study from 2011 to 2018. Oncologist 26, 514\u2013522 (2021).","journal-title":"Oncologist"},{"key":"1001_CR14","doi-asserted-by":"publisher","first-page":"639","DOI":"10.1002\/ijc.32132","volume":"145","author":"P Arnaud\u2010Coffin","year":"2019","unstructured":"Arnaud\u2010Coffin, P. et al. A systematic review of adverse events in randomized trials assessing immune checkpoint inhibitors. Int. J. Cancer 145, 639\u2013648 (2019).","journal-title":"Int. J. Cancer"},{"key":"1001_CR15","doi-asserted-by":"publisher","DOI":"10.1136\/jitc-2020-000992","volume":"8","author":"O Abu-Shawer","year":"2020","unstructured":"Abu-Shawer, O. et al. Novel platform leveraging electronic medical record (EMR) to triage patients admitted with high-grade immune-related adverse events (irAEs) to the immune-toxicity (ITOX) service. J. Immunother. Cancer 8, e000992 (2020).","journal-title":"J. Immunother. Cancer"},{"key":"1001_CR16","doi-asserted-by":"publisher","first-page":"fcab220","DOI":"10.1093\/braincomms\/fcab220","volume":"3","author":"L Pla\u00e7ais","year":"2021","unstructured":"Pla\u00e7ais, L. et al. Neurological complications induced by immune checkpoint inhibitors: a comprehensive descriptive case-series unravelling high risk of long-term sequelae. Brain Commun. 3, fcab220 (2021).","journal-title":"Brain Commun."},{"key":"1001_CR17","doi-asserted-by":"publisher","first-page":"659","DOI":"10.1002\/ana.25708","volume":"87","author":"D Dubey","year":"2020","unstructured":"Dubey, D. et al. Severe neurological toxicity of immune checkpoint inhibitors: growing spectrum. Ann. Neurol. 87, 659\u2013669 (2020).","journal-title":"Ann. Neurol."},{"key":"1001_CR18","doi-asserted-by":"publisher","first-page":"2975","DOI":"10.1007\/s00415-023-11625-1","volume":"270","author":"S Rossi","year":"2023","unstructured":"Rossi, S. et al. Peripheral nervous system adverse events associated with immune checkpoint inhibitors. J. Neurol. 270, 2975\u20132986 (2023).","journal-title":"J. Neurol."},{"key":"1001_CR19","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1016\/j.ejca.2016.12.001","volume":"73","author":"S Cuzzubbo","year":"2016","unstructured":"Cuzzubbo, S. et al. Neurological adverse events associated with immune checkpoint inhibitors: review of the literature. Eur. J. Cancer 73, 1\u20138 (2016).","journal-title":"Eur. J. Cancer"},{"key":"1001_CR20","doi-asserted-by":"publisher","first-page":"5583","DOI":"10.1007\/s00432-022-04516-x","volume":"149","author":"J-W Hyun","year":"2023","unstructured":"Hyun, J.-W., Kim, K. H., Kim, S.-H. & Kim, H. J. Severe neuromuscular immune-related adverse events of immune checkpoint inhibitors at National Cancer Center in Korea. J. Cancer Res. Clin. Oncol. 149, 5583\u20135589 (2023).","journal-title":"J. Cancer Res. Clin. Oncol."},{"key":"1001_CR21","doi-asserted-by":"publisher","first-page":"1721","DOI":"10.1001\/jamaoncol.2018.3923","volume":"4","author":"DY Wang","year":"2018","unstructured":"Wang, D. Y. et al. Fatal toxic effects associated with immune checkpoint inhibitors: a systematic review and meta-analysis. JAMA Oncol. 4, 1721\u20131728 (2018).","journal-title":"JAMA Oncol."},{"key":"1001_CR22","doi-asserted-by":"publisher","first-page":"fcad169","DOI":"10.1093\/braincomms\/fcad169","volume":"5","author":"A Farina","year":"2023","unstructured":"Farina, A. et al. Neurological outcomes in immune checkpoint inhibitor-related neurotoxicity. Brain Commun. 5, fcad169 (2023).","journal-title":"Brain Commun."},{"key":"1001_CR23","doi-asserted-by":"publisher","first-page":"1216","DOI":"10.1001\/jamaneurol.2017.1912","volume":"74","author":"JC Kao","year":"2017","unstructured":"Kao, J. C. et al. Neurological complications associated with anti\u2013programmed death 1 (PD-1) antibodies. JAMA Neurol. 74, 1216\u20131222 (2017).","journal-title":"JAMA Neurol."},{"key":"1001_CR24","doi-asserted-by":"publisher","first-page":"345","DOI":"10.1097\/WCO.0000000000001259","volume":"37","author":"A Farina","year":"2024","unstructured":"Farina, A., Villagr\u00e1n-Garc\u00eda, M., Vogrig, A. & Joubert, B. Central nervous system adverse events of immune checkpoint inhibitors. Curr. Opin. Neurol. 37, 345\u2013352 (2024).","journal-title":"Curr. Opin. Neurol."},{"key":"1001_CR25","doi-asserted-by":"publisher","DOI":"10.1136\/jitc-2021-002890","volume":"9","author":"AC Guidon","year":"2021","unstructured":"Guidon, A. C. et al. Consensus disease definitions for neurologic immune-related adverse events of immune checkpoint inhibitors. J. Immunother. Cancer 9, e002890 (2021).","journal-title":"J. Immunother. Cancer"},{"key":"1001_CR26","doi-asserted-by":"publisher","first-page":"e1093","DOI":"10.1212\/WNL.0000000000008091","volume":"93","author":"D Dubey","year":"2019","unstructured":"Dubey, D. et al. Varied phenotypes and management of immune checkpoint inhibitor\u2014a neuropathies. Neurology 93, e1093\u2013e1103 (2019).","journal-title":"Neurology"},{"key":"1001_CR27","doi-asserted-by":"publisher","first-page":"754","DOI":"10.1212\/WNL.0000000000011795","volume":"96","author":"A Marini","year":"2021","unstructured":"Marini, A. et al. Neurologic adverse events of immune checkpoint inhibitors: a systematic review. Neurology 96, 754\u2013766 (2021).","journal-title":"Neurology"},{"key":"1001_CR28","doi-asserted-by":"publisher","first-page":"e2442","DOI":"10.1212\/WNL.0000000000010632","volume":"95","author":"E Sechi","year":"2020","unstructured":"Sechi, E. et al. Neurologic autoimmunity and immune checkpoint inhibitors: autoantibody profiles and outcomes. Neurology 95, e2442\u2013e2452 (2020).","journal-title":"Neurology"},{"key":"1001_CR29","doi-asserted-by":"publisher","first-page":"1134436","DOI":"10.3389\/fimmu.2023.1134436","volume":"14","author":"R Ruggiero","year":"2023","unstructured":"Ruggiero, R. et al. Do peripheral neuropathies differ among immune checkpoint inhibitors? Reports from the European post-marketing surveillance database in the past 10\u2009years. Front. Immunol. 14, 1134436 (2023).","journal-title":"Front. Immunol."},{"key":"1001_CR30","doi-asserted-by":"publisher","first-page":"1657","DOI":"10.1056\/NEJMra2023935","volume":"383","author":"AA Amato","year":"2020","unstructured":"Amato, A. A. & Ropper, A. H. Sensory ganglionopathy. N. Engl. J. Med. 383, 1657\u20131662 (2020).","journal-title":"N. Engl. J. Med."},{"key":"1001_CR31","doi-asserted-by":"publisher","first-page":"112","DOI":"10.1136\/jnnp-2021-326369","volume":"93","author":"P Chompoopong","year":"2022","unstructured":"Chompoopong, P. et al. Comparison of immune checkpoint inhibitor-related neuropathies among patients with neuroendocrine and non-neuroendocrine tumours. J. Neurol. Neurosurg. Psychiatry 93, 112 (2022).","journal-title":"J. Neurol. Neurosurg. Psychiatry"},{"key":"1001_CR32","doi-asserted-by":"publisher","first-page":"71","DOI":"10.1016\/0022-510X(77)90183-6","volume":"33","author":"NB L\u00f6ffel","year":"1977","unstructured":"L\u00f6ffel, N. B., Rossi, L. N., Mumenthaler, M., L\u00fctschg, J. & Ludin, H.-P. The Landry\u2013Guillain\u2013Barr\u00e9 syndrome: complications, prognosis and natural history in 123 cases. J. Neurol. Sci. 33, 71\u201379 (1977).","journal-title":"J. Neurol. Sci."},{"key":"1001_CR33","doi-asserted-by":"publisher","first-page":"e985","DOI":"10.1212\/WNL.0000000000006124","volume":"91","author":"M Touat","year":"2018","unstructured":"Touat, M. et al. Immune checkpoint inhibitor-related myositis and myocarditis in patients with cancer. Neurology 91, e985\u2013e994 (2018).","journal-title":"Neurology"},{"key":"1001_CR34","doi-asserted-by":"publisher","first-page":"105","DOI":"10.1016\/j.jaut.2019.03.005","volume":"100","author":"M Seki","year":"2019","unstructured":"Seki, M. et al. Inflammatory myopathy associated with PD-1 inhibitors. J. Autoimmun. 100, 105\u2013113 (2019).","journal-title":"J. Autoimmun."},{"key":"1001_CR35","doi-asserted-by":"publisher","first-page":"fcaa181","DOI":"10.1093\/braincomms\/fcaa181","volume":"2","author":"S Shelly","year":"2020","unstructured":"Shelly, S. et al. Immune checkpoint inhibitor-associated myopathy: a clinicoseropathologically distinct myopathy. Brain Commun. 2, fcaa181 (2020).","journal-title":"Brain Commun."},{"key":"1001_CR36","doi-asserted-by":"publisher","first-page":"1127","DOI":"10.1212\/WNL.0000000000004359","volume":"89","author":"S Suzuki","year":"2017","unstructured":"Suzuki, S. et al. Nivolumab-related myasthenia gravis with myositis and myocarditis in Japan. Neurology 89, 1127\u20131134 (2017).","journal-title":"Neurology"},{"key":"1001_CR37","doi-asserted-by":"publisher","first-page":"866","DOI":"10.1002\/art.41604","volume":"73","author":"J Aldrich","year":"2021","unstructured":"Aldrich, J. et al. Inflammatory myositis in cancer patients receiving immune checkpoint inhibitors. Arthritis Rheumatol. 73, 866\u2013874 (2021).","journal-title":"Arthritis Rheumatol."},{"key":"1001_CR38","doi-asserted-by":"publisher","first-page":"829","DOI":"10.1136\/ard-2022-223792","volume":"82","author":"I Pinal-Fernandez","year":"2023","unstructured":"Pinal-Fernandez, I. et al. Transcriptomic profiling reveals distinct subsets of immune checkpoint inhibitor induced myositis. Ann. Rheum. Dis. 82, 829\u2013836 (2023).","journal-title":"Ann. Rheum. Dis."},{"key":"1001_CR39","doi-asserted-by":"publisher","first-page":"663","DOI":"10.1212\/WNL.0000000000007235","volume":"92","author":"A Johansen","year":"2019","unstructured":"Johansen, A., Christensen, S. J., Scheie, D., H\u00f8jgaard, J. L. S. & Kondziella, D. Neuromuscular adverse events associated with anti-PD-1 monoclonal antibodies: systematic review. Neurology 92, 663\u2013674 (2019).","journal-title":"Neurology"},{"key":"1001_CR40","doi-asserted-by":"publisher","first-page":"634","DOI":"10.3389\/fneur.2020.00634","volume":"11","author":"Y-T Huang","year":"2020","unstructured":"Huang, Y.-T., Chen, Y.-P., Lin, W.-C., Su, W.-C. & Sun, Y.-T. Immune checkpoint inhibitor-induced myasthenia gravis. Front. Neurol. 11, 634 (2020).","journal-title":"Front. Neurol."},{"key":"1001_CR41","doi-asserted-by":"publisher","first-page":"e402","DOI":"10.1093\/oncolo\/oyac033","volume":"27","author":"JY Rhee","year":"2022","unstructured":"Rhee, J. Y., Torun, N., Neilan, T. G. & Guidon, A. C. Consider myocarditis when patients treated with immune checkpoint inhibitors present with ocular symptoms. Oncologist 27, e402\u2013e405 (2022).","journal-title":"Oncologist"},{"key":"1001_CR42","doi-asserted-by":"publisher","first-page":"435","DOI":"10.1634\/theoncologist.2018-0359","volume":"24","author":"KL Reynolds","year":"2019","unstructured":"Reynolds, K. L. & Guidon, A. C. Diagnosis and management of immune checkpoint inhibitor\u2010associated neurologic toxicity: illustrative case and review of the literature. Oncologist 24, 435\u2013443 (2019).","journal-title":"Oncologist"},{"key":"1001_CR43","doi-asserted-by":"publisher","first-page":"1041","DOI":"10.1093\/rheumatology\/key031","volume":"57","author":"JB Lilleker","year":"2018","unstructured":"Lilleker, J. B. et al. Using serum troponins to screen for cardiac involvement and assess disease activity in the idiopathic inflammatory myopathies. Rheumatology 57, 1041\u20131046 (2018).","journal-title":"Rheumatology"},{"key":"1001_CR44","doi-asserted-by":"publisher","first-page":"1329","DOI":"10.1001\/jamacardio.2021.2241","volume":"6","author":"LH Lehmann","year":"2021","unstructured":"Lehmann, L. H. et al. Clinical strategy for the diagnosis and treatment of immune checkpoint inhibitor-associated myocarditis: a narrative review. JAMA Cardiol. 6, 1329\u20131337 (2021).","journal-title":"JAMA Cardiol."},{"key":"1001_CR45","doi-asserted-by":"publisher","first-page":"130","DOI":"10.3390\/jcm12010130","volume":"12","author":"C Marco","year":"2022","unstructured":"Marco, C. et al. Myasthenia gravis induced by immune checkpoint inhibitors: an emerging neurotoxicity in neuro-oncology practice: case series. J. Clin. Med. 12, 130 (2022).","journal-title":"J. Clin. Med."},{"key":"1001_CR46","doi-asserted-by":"publisher","DOI":"10.1212\/WNL.0000000000207863","volume":"102","author":"AA Habib","year":"2024","unstructured":"Habib, A. A. et al. Hospitalizations and mortality from myasthenia gravis: trends from 2 US national datasets. Neurology 102, e207863 (2024).","journal-title":"Neurology"},{"key":"1001_CR47","doi-asserted-by":"publisher","first-page":"825","DOI":"10.1002\/acn3.51761","volume":"10","author":"G Masi","year":"2023","unstructured":"Masi, G. et al. Clinicoserological insights into patients with immune checkpoint inhibitor\u2010induced myasthenia gravis. Ann. Clin. Transl. Neurol. 10, 825\u2013831 (2023).","journal-title":"Ann. Clin. Transl. Neurol."},{"key":"1001_CR48","doi-asserted-by":"publisher","first-page":"150","DOI":"10.1136\/annrheumdis-2018-213777","volume":"78","author":"AL Mammen","year":"2019","unstructured":"Mammen, A. L. et al. Pre-existing antiacetylcholine receptor autoantibodies and B cell lymphopaenia are associated with the development of myositis in patients with thymoma treated with avelumab, an immune checkpoint inhibitor targeting programmed death-ligand 1. Ann. Rheum. Dis. 78, 150\u2013152 (2019).","journal-title":"Ann. Rheum. Dis."},{"key":"1001_CR49","first-page":"1615","volume":"28","author":"K Hehir Michael II","year":"2022","unstructured":"Hehir Michael, K. II & Li, Y. Diagnosis and management of myasthenia gravis. Continuum 28, 1615\u20131642 (2022).","journal-title":"Continuum"},{"key":"1001_CR50","doi-asserted-by":"publisher","first-page":"319","DOI":"10.1186\/s40425-019-0774-y","volume":"7","author":"H Safa","year":"2019","unstructured":"Safa, H. et al. Immune checkpoint inhibitor related myasthenia gravis: single center experience and systematic review of the literature. J. Immunother. Cancer 7, 319 (2019).","journal-title":"J. Immunother. Cancer"},{"key":"1001_CR51","doi-asserted-by":"publisher","first-page":"1893","DOI":"10.2169\/internalmedicine.9153-17","volume":"57","author":"A Mitsune","year":"2018","unstructured":"Mitsune, A. et al. Relapsed myasthenia gravis after nivolumab treatment. Intern. Med. 57, 1893\u20131897 (2018).","journal-title":"Intern. Med."},{"key":"1001_CR52","first-page":"151","volume":"13","author":"Y Shames","year":"2022","unstructured":"Shames, Y., Errante, M. & Keteku, N. P. Myasthenia gravis: a rare neurologic complication of immune checkpoint inhibitor therapy. J. Adv. Pract. Oncol. 13, 151\u2013157 (2022).","journal-title":"J. Adv. Pract. Oncol."},{"key":"1001_CR53","doi-asserted-by":"publisher","first-page":"568","DOI":"10.1038\/nature13954","volume":"515","author":"PC Tumeh","year":"2014","unstructured":"Tumeh, P. C. et al. PD-1 blockade induces responses by inhibiting adaptive immune resistance. Nature 515, 568\u2013571 (2014).","journal-title":"Nature"},{"key":"1001_CR54","doi-asserted-by":"publisher","first-page":"11919","DOI":"10.1073\/pnas.1611421113","volume":"113","author":"SK Subudhi","year":"2016","unstructured":"Subudhi, S. K. et al. Clonal expansion of CD8 T cells in the systemic circulation precedes development of ipilimumab-induced toxicities. Proc. Natl Acad. Sci. USA 113, 11919\u201311924 (2016).","journal-title":"Proc. Natl Acad. Sci. USA"},{"key":"1001_CR55","doi-asserted-by":"publisher","first-page":"1749","DOI":"10.1056\/NEJMoa1609214","volume":"375","author":"DB Johnson","year":"2016","unstructured":"Johnson, D. B. et al. Fulminant myocarditis with combination immune checkpoint blockade. N. Engl. J. Med. 375, 1749\u20131755 (2016).","journal-title":"N. Engl. J. Med."},{"key":"1001_CR56","doi-asserted-by":"publisher","first-page":"1100","DOI":"10.1158\/2159-8290.CD-22-1180","volume":"13","author":"J-E Salem","year":"2023","unstructured":"Salem, J.-E. et al. Abatacept\/ruxolitinib and screening for concomitant respiratory muscle failure to mitigate fatality of immune-checkpoint inhibitor myocarditis. Cancer Discov. 13, 1100\u20131115 (2023).","journal-title":"Cancer Discov."},{"key":"1001_CR57","doi-asserted-by":"publisher","first-page":"655","DOI":"10.1016\/j.cell.2020.06.001","volume":"182","author":"AM Luoma","year":"2020","unstructured":"Luoma, A. M. et al. Molecular pathways of colon inflammation induced by cancer immunotherapy. Cell 182, 655\u2013671.e22 (2020).","journal-title":"Cell"},{"key":"1001_CR58","doi-asserted-by":"publisher","first-page":"1229.e9","DOI":"10.1053\/j.gastro.2021.06.025","volume":"161","author":"SC Sasson","year":"2021","unstructured":"Sasson, S. C. et al. Interferon-\u03b3-producing CD8+ tissue resident memory T cells are a targetable hallmark of immune checkpoint inhibitor colitis. Gastroenterology 161, 1229.e9\u20131244.e9 (2021).","journal-title":"Gastroenterology"},{"key":"1001_CR59","doi-asserted-by":"publisher","first-page":"1043","DOI":"10.1001\/jamaoncol.2019.0402","volume":"5","author":"F Berner","year":"2019","unstructured":"Berner, F. et al. Association of checkpoint inhibitor-induced toxic effects with shared cancer and tissue antigens in non-small cell lung cancer. JAMA Oncol. 5, 1043\u20131047 (2019).","journal-title":"JAMA Oncol."},{"key":"1001_CR60","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1001\/jamadermatol.2015.2707","volume":"152","author":"C Hua","year":"2016","unstructured":"Hua, C. et al. Association of vitiligo with tumor response in patients with metastatic melanoma treated with pembrolizumab. JAMA Dermatol. 152, 1\u20137 (2016).","journal-title":"JAMA Dermatol."},{"key":"1001_CR61","doi-asserted-by":"publisher","first-page":"535","DOI":"10.1038\/s41571-019-0194-4","volume":"16","author":"F Graus","year":"2019","unstructured":"Graus, F. & Dalmau, J. Paraneoplastic neurological syndromes in the era of immune-checkpoint inhibitors. Nat. Rev. Clin. Oncol. 16, 535\u2013548 (2019).","journal-title":"Nat. Rev. Clin. Oncol."},{"key":"1001_CR62","doi-asserted-by":"publisher","DOI":"10.1212\/NXI.0000000000200058","volume":"10","author":"A Farina","year":"2023","unstructured":"Farina, A. et al. Anti-Hu antibodies in patients with neurologic side effects of immune checkpoint inhibitors. Neurol. Neuroimmunol. Neuroinflamm 10, e200058 (2023).","journal-title":"Neurol. Neuroimmunol. Neuroinflamm"},{"key":"1001_CR63","doi-asserted-by":"publisher","first-page":"81","DOI":"10.1016\/S1474-4422(23)00369-1","volume":"23","author":"A Farina","year":"2024","unstructured":"Farina, A. et al. Neurological adverse events of immune checkpoint inhibitors and the development of paraneoplastic neurological syndromes. Lancet Neurol. 23, 81\u201394 (2024).","journal-title":"Lancet Neurol."},{"key":"1001_CR64","doi-asserted-by":"publisher","first-page":"E18","DOI":"10.1002\/mus.27141","volume":"63","author":"AJ Gill","year":"2021","unstructured":"Gill, A. J., Gandhy, S. & Lancaster, E. Nivolumab\u2010associated Lambert\u2013Eaton myasthenic syndrome and cerebellar dysfunction in a patient with a neuroendocrine tumor. Muscle Nerve 63, E18\u2013E21 (2021).","journal-title":"Muscle Nerve"},{"key":"1001_CR65","doi-asserted-by":"publisher","first-page":"086","DOI":"10.21926\/obm.neurobiol.2101086","volume":"5","author":"CJ Anderson","year":"2021","unstructured":"Anderson, C. J. et al. Case report of Lambert\u2013Eaton myasthenic syndrome in a patient with small cell lung cancer on immune checkpoint inhibitor therapy. OBM Neurobiol. 5, 086 (2021).","journal-title":"OBM Neurobiol."},{"key":"1001_CR66","doi-asserted-by":"publisher","first-page":"346","DOI":"10.1159\/000494078","volume":"10","author":"Y Nakatani","year":"2018","unstructured":"Nakatani, Y. et al. Lambert\u2013Eaton myasthenic syndrome caused by nivolumab in a patient with squamous cell lung cancer. Case Rep. Neurol. 10, 346\u2013352 (2018).","journal-title":"Case Rep. Neurol."},{"key":"1001_CR67","doi-asserted-by":"publisher","first-page":"337","DOI":"10.1186\/s40425-019-0821-8","volume":"7","author":"G Manson","year":"2019","unstructured":"Manson, G. et al. Worsening and newly diagnosed paraneoplastic syndromes following anti-PD-1 or anti-PD-L1 immunotherapies, a descriptive study. J. Immunother. Cancer 7, 337 (2019).","journal-title":"J. Immunother. Cancer"},{"key":"1001_CR68","doi-asserted-by":"publisher","first-page":"577184","DOI":"10.1016\/j.jneuroim.2020.577184","volume":"341","author":"P Raibagkar","year":"2020","unstructured":"Raibagkar, P., Ho, D., Gunturu, K. S. & Srinivasan, J. Worsening of anti-Hu paraneoplastic neurological syndrome related to anti-PD-1 treatment: case report and review of literature. J. Neuroimmunol. 341, 577184 (2020).","journal-title":"J. Neuroimmunol."},{"key":"1001_CR69","doi-asserted-by":"publisher","first-page":"254ra128","DOI":"10.1126\/scitranslmed.3008918","volume":"6","author":"P Kvistborg","year":"2014","unstructured":"Kvistborg, P. et al. Anti-CTLA-4 therapy broadens the melanoma-reactive CD8+ T cell response. Sci. Transl. Med. 6, 254ra128 (2014).","journal-title":"Sci. Transl. Med."},{"key":"1001_CR70","doi-asserted-by":"publisher","first-page":"1322","DOI":"10.1158\/0008-5472.CAN-16-2324","volume":"77","author":"DY Oh","year":"2017","unstructured":"Oh, D. Y. et al. Immune toxicities elicted by CTLA-4 blockade in cancer patients are associated with early diversification of the T-cell repertoire. Cancer Res. 77, 1322\u20131330 (2017).","journal-title":"Cancer Res."},{"key":"1001_CR71","doi-asserted-by":"publisher","first-page":"85","DOI":"10.1038\/nri724","volume":"2","author":"SD Miller","year":"2002","unstructured":"Miller, S. D. & Vanderlugt, C. L. Epitope spreading in immune-mediated diseases: implications for immunotherapy. Nat. Rev. Immunol. 2, 85\u201395 (2002).","journal-title":"Nat. Rev. Immunol."},{"key":"1001_CR72","doi-asserted-by":"publisher","first-page":"540","DOI":"10.1038\/nm.4321","volume":"23","author":"CH June","year":"2017","unstructured":"June, C. H., Warshauer, J. T. & Bluestone, J. A. Is autoimmunity the Achilles\u2019 heel of cancer immunotherapy? Nat. Med. 23, 540\u2013547 (2017).","journal-title":"Nat. Med."},{"key":"1001_CR73","doi-asserted-by":"publisher","first-page":"818","DOI":"10.1038\/s41586-022-05432-3","volume":"611","author":"ML Axelrod","year":"2022","unstructured":"Axelrod, M. L. et al. T cells specific for \u03b1-myosin drive immunotherapy-related myocarditis. Nature 611, 818\u2013826 (2022).","journal-title":"Nature"},{"key":"1001_CR74","doi-asserted-by":"publisher","first-page":"177","DOI":"10.1016\/S0165-5728(03)00078-X","volume":"137","author":"S Suzuki","year":"2003","unstructured":"Suzuki, S. et al. Autoreactive T cells to the P3A+ isoform of AChR \u03b1 subunit in myasthenia gravis. J. Neuroimmunol. 137, 177\u2013186 (2003).","journal-title":"J. Neuroimmunol."},{"key":"1001_CR75","doi-asserted-by":"publisher","first-page":"1040","DOI":"10.1158\/2159-8290.CD-23-0199","volume":"13","author":"M Dougan","year":"2023","unstructured":"Dougan, M. Weighing antitumor immunity against life-threatening myocarditis from immune-checkpoint inhibitors. Cancer Discov. 13, 1040\u20131042 (2023).","journal-title":"Cancer Discov."},{"key":"1001_CR76","doi-asserted-by":"publisher","first-page":"7571","DOI":"10.21037\/jtd-2019-thym-10","volume":"12","author":"TG Blum","year":"2020","unstructured":"Blum, T. G., Misch, D., Kollmeier, J., Thiel, S. & Bauer, T. T. Autoimmune disorders and paraneoplastic syndromes in thymoma. J. Thorac. Dis. 12, 7571\u20137590 (2020).","journal-title":"J. Thorac. Dis."},{"key":"1001_CR77","doi-asserted-by":"publisher","first-page":"29","DOI":"10.1016\/j.lungcan.2019.06.015","volume":"135","author":"T Konstantina","year":"2019","unstructured":"Konstantina, T. et al. Fatal adverse events in two thymoma patients treated with anti-PD-1 immune check point inhibitor and literature review. Lung Cancer 135, 29\u201332 (2019).","journal-title":"Lung Cancer"},{"key":"1001_CR78","doi-asserted-by":"publisher","first-page":"168","DOI":"10.1016\/j.canlet.2019.05.003","volume":"457","author":"R Saleh","year":"2019","unstructured":"Saleh, R. & Elkord, E. Treg-mediated acquired resistance to immune checkpoint inhibitors. Cancer Lett. 457, 168\u2013179 (2019).","journal-title":"Cancer Lett."},{"key":"1001_CR79","doi-asserted-by":"publisher","first-page":"2061","DOI":"10.1136\/annrheumdis-2017-211560","volume":"76","author":"ST Kim","year":"2017","unstructured":"Kim, S. T. et al. Successful treatment of arthritis induced by checkpoint inhibitors with tocilizumab: a case series. Ann. Rheum. Dis. 76, 2061\u20132064 (2017).","journal-title":"Ann. Rheum. Dis."},{"key":"1001_CR80","doi-asserted-by":"publisher","first-page":"726","DOI":"10.1158\/2326-6066.CIR-20-0969","volume":"9","author":"M Grigoriou","year":"2021","unstructured":"Grigoriou, M. et al. Regulatory T-cell transcriptomic reprogramming characterizes adverse events by checkpoint inhibitors in solid tumors. Cancer Immunol. Res. 9, 726\u2013734 (2021).","journal-title":"Cancer Immunol. Res."},{"key":"1001_CR81","doi-asserted-by":"publisher","first-page":"1563","DOI":"10.1093\/intimm\/10.10.1563","volume":"10","author":"H Nishimura","year":"1998","unstructured":"Nishimura, H., Minato, N., Nakano, T. & Honjo, T. Immunological studies on PD-1-deficient mice: implication of PD-1 as a negative regulator for B cell responses. Int. Immunol. 10, 1563\u20131572 (1998).","journal-title":"Int. Immunol."},{"key":"1001_CR82","doi-asserted-by":"publisher","first-page":"556","DOI":"10.1038\/s41586-019-1906-8","volume":"577","author":"F Petitprez","year":"2020","unstructured":"Petitprez, F. et al. B cells are associated with survival and immunotherapy response in sarcoma. Nature 577, 556\u2013560 (2020).","journal-title":"Nature"},{"key":"1001_CR83","doi-asserted-by":"publisher","first-page":"715","DOI":"10.1172\/JCI96798","volume":"128","author":"R Das","year":"2018","unstructured":"Das, R. et al. Early B cell changes predict autoimmunity following combination immune checkpoint blockade. J. Clin. Invest. 128, 715\u2013720 (2018).","journal-title":"J. Clin. Invest."},{"key":"1001_CR84","doi-asserted-by":"publisher","first-page":"549","DOI":"10.1038\/s41586-019-1922-8","volume":"577","author":"BA Helmink","year":"2020","unstructured":"Helmink, B. A. et al. B cells and tertiary lymphoid structures promote immunotherapy response. Nature 577, 549\u2013555 (2020).","journal-title":"Nature"},{"key":"1001_CR85","doi-asserted-by":"publisher","first-page":"6","DOI":"10.1158\/2326-6066.CIR-18-0245","volume":"7","author":"EC de Moel","year":"2019","unstructured":"de Moel, E. C. et al. Autoantibody development under treatment with immune-checkpoint inhibitors. Cancer Immunol. Res. 7, 6\u201311 (2019).","journal-title":"Cancer Immunol. Res."},{"key":"1001_CR86","doi-asserted-by":"publisher","first-page":"411","DOI":"10.3389\/fimmu.2018.00411","volume":"9","author":"JDG Duarte","year":"2018","unstructured":"Duarte, J. D. G. et al. Autoantibodies may predict immune-related toxicity: results from a phase I study of intralesional Bacillus Calmette\u2013Guerin followed by ipilimumab in patients with advanced metastatic melanoma. Front. Immunol. 9, 411 (2018).","journal-title":"Front. Immunol."},{"key":"1001_CR87","doi-asserted-by":"publisher","DOI":"10.1038\/s41467-022-30863-x","volume":"13","author":"AJ Patel","year":"2022","unstructured":"Patel, A. J. et al. Regulatory B cell repertoire defects predispose lung cancer patients to immune-related toxicity following checkpoint blockade. Nat. Commun. 13, 3148 (2022).","journal-title":"Nat. Commun."},{"key":"1001_CR88","doi-asserted-by":"publisher","first-page":"21","DOI":"10.1016\/j.ejca.2017.12.008","volume":"91","author":"F-X Danlos","year":"2018","unstructured":"Danlos, F.-X. et al. Safety and efficacy of anti-programmed death 1 antibodies in patients with cancer and pre-existing autoimmune or inflammatory disease. Eur. J. Cancer 91, 21\u201329 (2018).","journal-title":"Eur. J. Cancer"},{"key":"1001_CR89","doi-asserted-by":"publisher","first-page":"368","DOI":"10.1093\/annonc\/mdw443","volume":"28","author":"AM Menzies","year":"2017","unstructured":"Menzies, A. M. et al. Anti-PD-1 therapy in patients with advanced melanoma and preexisting autoimmune disorders or major toxicity with ipilimumab. Ann. Oncol. 28, 368\u2013376 (2017).","journal-title":"Ann. Oncol."},{"key":"1001_CR90","doi-asserted-by":"publisher","first-page":"24","DOI":"10.1016\/j.ejca.2016.12.038","volume":"75","author":"R Gutzmer","year":"2017","unstructured":"Gutzmer, R. et al. Programmed cell death protein-1 (PD-1) inhibitor therapy in patients with advanced melanoma and preexisting autoimmunity or ipilimumab-triggered autoimmunity. Eur. J. Cancer 75, 24\u201332 (2017).","journal-title":"Eur. J. Cancer"},{"key":"1001_CR91","doi-asserted-by":"publisher","first-page":"234","DOI":"10.1001\/jamaoncol.2015.4368","volume":"2","author":"DB Johnson","year":"2016","unstructured":"Johnson, D. B. et al. Ipilimumab therapy in patients with advanced melanoma and preexisting autoimmune disorders. JAMA Oncol. 2, 234\u2013240 (2016).","journal-title":"JAMA Oncol."},{"key":"1001_CR92","doi-asserted-by":"publisher","first-page":"4073","DOI":"10.1200\/JCO.21.01440","volume":"39","author":"BJ Schneider","year":"2021","unstructured":"Schneider, B. J. et al. Management of immune-related adverse events in patients treated with immune checkpoint inhibitor therapy: ASCO guideline update. J. Clin. Oncol. 39, 4073\u20134126 (2021).","journal-title":"J. Clin. Oncol."},{"key":"1001_CR93","doi-asserted-by":"publisher","first-page":"114","DOI":"10.1212\/WNL.0000000000011124","volume":"96","author":"P Narayanaswami","year":"2020","unstructured":"Narayanaswami, P. et al. International consensus guidance for management of myasthenia gravis: 2020 update. Neurology 96, 114\u2013122 (2020).","journal-title":"Neurology"},{"key":"1001_CR94","doi-asserted-by":"publisher","DOI":"10.1136\/jitc-2019-000356","volume":"8","author":"P Boland","year":"2020","unstructured":"Boland, P., Pavlick, A. C., Weber, J. & Sandigursky, S. Immunotherapy to treat malignancy in patients with pre-existing autoimmunity. J. Immunother. Cancer 8, e000356 (2020).","journal-title":"J. Immunother. Cancer"},{"key":"1001_CR95","doi-asserted-by":"publisher","DOI":"10.1136\/jitc-2021-002435","volume":"9","author":"JR Brahmer","year":"2021","unstructured":"Brahmer, J. R. et al. Society for Immunotherapy of Cancer (SITC) clinical practice guideline on immune checkpoint inhibitor-related adverse events. J. Immunother. Cancer 9, e002435 (2021).","journal-title":"J. Immunother. Cancer"},{"key":"1001_CR96","doi-asserted-by":"publisher","first-page":"387","DOI":"10.6004\/jnccn.2022.0020","volume":"20","author":"JA Thompson","year":"2022","unstructured":"Thompson, J. A. et al. Management of immunotherapy-related toxicities, version 1.2022, NCCN Clinical Practice Guidelines in Oncology. J. Natl Compr. Cancer Netw. 20, 387\u2013405 (2022).","journal-title":"J. Natl Compr. Cancer Netw."},{"key":"1001_CR97","doi-asserted-by":"publisher","first-page":"1217","DOI":"10.1016\/j.annonc.2022.10.001","volume":"33","author":"J Haanen","year":"2022","unstructured":"Haanen, J. et al. Management of toxicities from immunotherapy: ESMO Clinical Practice Guideline for diagnosis, treatment and follow-up. Ann. Oncol. 33, 1217\u20131238 (2022).","journal-title":"Ann. Oncol."},{"key":"1001_CR98","doi-asserted-by":"publisher","first-page":"2","DOI":"10.1016\/j.mce.2010.04.005","volume":"335","author":"AE Coutinho","year":"2011","unstructured":"Coutinho, A. E. & Chapman, K. E. The anti-inflammatory and immunosuppressive effects of glucocorticoids, recent developments and mechanistic insights. Mol. Cell Endocrinol. 335, 2\u201313 (2011).","journal-title":"Mol. Cell Endocrinol."},{"key":"1001_CR99","doi-asserted-by":"crossref","unstructured":"Kruh, J. & Foster, C. S. Corticosteroid-sparing agents: conventional systemic immunosuppressants. Devel. Ophthalmol. 51, 29\u201346 (2012).","DOI":"10.1159\/000336185"},{"key":"1001_CR100","doi-asserted-by":"publisher","first-page":"2031","DOI":"10.1161\/CIRCULATIONAHA.119.044703","volume":"141","author":"L Zhang","year":"2020","unstructured":"Zhang, L. et al. Major adverse cardiovascular events and the timing and dose of corticosteroids in immune checkpoint inhibitor-associated myocarditis. Circulation 141, 2031\u20132034 (2020).","journal-title":"Circulation"},{"key":"1001_CR101","doi-asserted-by":"publisher","first-page":"80","DOI":"10.1038\/nrneurol.2014.253","volume":"11","author":"JD Luenemann","year":"2015","unstructured":"Luenemann, J. D., Nimmerjahn, F. & Dalakas, M. C. Intravenous immunoglobulin in neurology\u2014mode of action and clinical efficacy. Nat. Rev. Neurol. 11, 80\u201389 (2015).","journal-title":"Nat. Rev. Neurol."},{"key":"1001_CR102","doi-asserted-by":"publisher","first-page":"282","DOI":"10.1016\/j.annonc.2020.12.001","volume":"32","author":"SN Deftereos","year":"2021","unstructured":"Deftereos, S. N. & Georgonikou, D. Effectiveness of rituximab in treating immune-checkpoint-inhibitor-induced immune-related adverse events: results of a systematic review. Ann. Oncol. 32, 282\u2013283 (2021).","journal-title":"Ann. Oncol."},{"key":"1001_CR103","first-page":"CD002063","volume":"2019","author":"RAC Hughes","year":"2014","unstructured":"Hughes, R. A. C., Swan, A. V. & van Doorn, P. Intravenous immunoglobulin for Guillain\u2013Barr\u00e9 syndrome. Cochrane Datab. Syst. Rev. 2019, CD002063 (2014).","journal-title":"Cochrane Datab. Syst. Rev."},{"key":"1001_CR104","doi-asserted-by":"publisher","first-page":"419","DOI":"10.1212\/WNL.0000000000002790","volume":"87","author":"DB Sanders","year":"2016","unstructured":"Sanders, D. B. et al. International consensus guidance for management of myasthenia gravis: executive summary. Neurology 87, 419\u2013425 (2016).","journal-title":"Neurology"},{"key":"1001_CR105","doi-asserted-by":"publisher","first-page":"2872","DOI":"10.1200\/JCO.2018.79.0006","volume":"36","author":"KC Arbour","year":"2018","unstructured":"Arbour, K. C. et al. Impact of baseline steroids on efficacy of programmed cell death-1 and programmed death-ligand 1 blockade in patients with non-small-cell lung cancer. J. Clin. Oncol. 36, 2872\u20132878 (2018).","journal-title":"J. Clin. Oncol."},{"key":"1001_CR106","doi-asserted-by":"publisher","first-page":"1771","DOI":"10.1016\/j.jtho.2018.06.004","volume":"13","author":"SC Scott","year":"2018","unstructured":"Scott, S. C. & Pennell, N. A. Early use of systemic corticosteroids in patients with advanced NSCLC treated with nivolumab. J. Thorac. Oncol. 13, 1771\u20131775 (2018).","journal-title":"J. Thorac. Oncol."},{"key":"1001_CR107","doi-asserted-by":"publisher","DOI":"10.1136\/esmoopen-2018-000457","volume":"4","author":"G Fuc\u00e0","year":"2019","unstructured":"Fuc\u00e0, G. et al. Modulation of peripheral blood immune cells by early use of steroids and its association with clinical outcomes in patients with metastatic non-small cell lung cancer treated with immune checkpoint inhibitors. ESMO Open. 4, e000457 (2019).","journal-title":"ESMO Open."},{"key":"1001_CR108","doi-asserted-by":"publisher","first-page":"3193","DOI":"10.1200\/JCO.2015.60.8448","volume":"33","author":"TZ Horvat","year":"2015","unstructured":"Horvat, T. Z. et al. Immune-related adverse events, need for systemic immunosuppression, and effects on survival and time to treatment failure in patients with melanoma treated with ipilimumab at Memorial Sloan Kettering Cancer Center. J. Clin. Oncol. 33, 3193\u20133198 (2015).","journal-title":"J. Clin. Oncol."},{"key":"1001_CR109","doi-asserted-by":"publisher","first-page":"785","DOI":"10.1200\/JCO.2015.66.1389","volume":"35","author":"JS Weber","year":"2017","unstructured":"Weber, J. S. et al. Safety profile of nivolumab monotherapy: a pooled analysis of patients with advanced melanoma. J. Clin. Oncol. 35, 785\u2013792 (2017).","journal-title":"J. Clin. Oncol."},{"key":"1001_CR110","doi-asserted-by":"publisher","first-page":"3706","DOI":"10.1002\/cncr.31629","volume":"124","author":"AT Faje","year":"2018","unstructured":"Faje, A. T. et al. High\u2010dose glucocorticoids for the treatment of ipilimumab\u2010induced hypophysitis is associated with reduced survival in patients with melanoma. Cancer 124, 3706\u20133714 (2018).","journal-title":"Cancer"},{"key":"1001_CR111","doi-asserted-by":"publisher","first-page":"523","DOI":"10.1111\/cas.13433","volume":"109","author":"H Tsukamoto","year":"2018","unstructured":"Tsukamoto, H. et al. Immune\u2010suppressive effects of interleukin\u20106 on T\u2010cell\u2010mediated anti\u2010tumor immunity. Cancer Sci. 109, 523\u2013530 (2018).","journal-title":"Cancer Sci."},{"key":"1001_CR112","doi-asserted-by":"publisher","first-page":"509.e6","DOI":"10.1016\/j.ccell.2022.04.004","volume":"40","author":"Y Hailemichael","year":"2022","unstructured":"Hailemichael, Y. et al. Interleukin-6 blockade abrogates immunotherapy toxicity and promotes tumor immunity. Cancer Cell 40, 509.e6\u2013523.e6 (2022).","journal-title":"Cancer Cell"},{"key":"1001_CR113","doi-asserted-by":"publisher","first-page":"1273","DOI":"10.1016\/j.annonc.2020.05.005","volume":"31","author":"J Doms","year":"2020","unstructured":"Doms, J., Prior, J. O., Peters, S. & Obeid, M. Tocilizumab for refractory severe immune checkpoint inhibitor-associated myocarditis. Ann. Oncol. 31, 1273\u20131275 (2020).","journal-title":"Ann. Oncol."},{"key":"1001_CR114","doi-asserted-by":"publisher","first-page":"e31","DOI":"10.1016\/j.jtho.2019.09.080","volume":"15","author":"H Wang","year":"2020","unstructured":"Wang, H., Tian, R., Gao, P., Wang, Q. & Zhang, L. Tocilizumab for fulminant programmed death 1 inhibitor-associated myocarditis. J. Thorac. Oncol. 15, e31\u2013e32 (2020).","journal-title":"J. Thorac. Oncol."},{"key":"1001_CR115","doi-asserted-by":"publisher","first-page":"1623","DOI":"10.1007\/s00432-021-03550-5","volume":"147","author":"B Husain","year":"2021","unstructured":"Husain, B. et al. Inflammatory markers in autoimmunity induced by checkpoint inhibitors. J. Cancer Res. Clin. Oncol. 147, 1623\u20131630 (2021).","journal-title":"J. Cancer Res. Clin. Oncol."},{"key":"1001_CR116","doi-asserted-by":"publisher","first-page":"213","DOI":"10.1038\/s41584-021-00584-4","volume":"17","author":"AY Chen","year":"2021","unstructured":"Chen, A. Y., Wolchok, J. D. & Bass, A. R. TNF in the era of immune checkpoint inhibitors: friend or foe? Nat. Rev. Rheumatol. 17, 213\u2013223 (2021).","journal-title":"Nat. Rev. Rheumatol."},{"key":"1001_CR117","doi-asserted-by":"publisher","first-page":"175","DOI":"10.1097\/CJI.0000000000000268","volume":"42","author":"C Lesage","year":"2019","unstructured":"Lesage, C. et al. Incidence and clinical impact of anti-TNF\u03b1 treatment of severe immune checkpoint inhibitor-induced colitis in advanced melanoma: the Mecolit survey. J. Immunother. 42, 175\u2013179 (2019).","journal-title":"J. Immunother."},{"key":"1001_CR118","doi-asserted-by":"publisher","first-page":"37","DOI":"10.1186\/s40425-018-0346-6","volume":"6","author":"Y Wang","year":"2018","unstructured":"Wang, Y. et al. Immune-checkpoint inhibitor-induced diarrhea and colitis in patients with advanced malignancies: retrospective review at MD Anderson. J. Immunother. Cancer 6, 37 (2018).","journal-title":"J. Immunother. Cancer"},{"key":"1001_CR119","doi-asserted-by":"publisher","first-page":"93","DOI":"10.1186\/s40425-019-0577-1","volume":"7","author":"H Abu-Sbeih","year":"2019","unstructured":"Abu-Sbeih, H. et al. Early introduction of selective immunosuppressive therapy associated with favorable clinical outcomes in patients with immune checkpoint inhibitor-induced colitis. J. Immunother. Cancer 7, 93 (2019).","journal-title":"J. Immunother. Cancer"},{"key":"1001_CR120","doi-asserted-by":"publisher","first-page":"1037","DOI":"10.1158\/1078-0432.CCR-20-3449","volume":"27","author":"A Montfort","year":"2021","unstructured":"Montfort, A. et al. Combining nivolumab and ipilimumab with infliximab or certolizumab in patients with advanced melanoma: first results of a phase Ib clinical trial. Clin. Cancer Res. 27, 1037\u20131047 (2021).","journal-title":"Clin. Cancer Res."},{"key":"1001_CR121","doi-asserted-by":"publisher","first-page":"279","DOI":"10.1038\/nrrheum.2018.42","volume":"14","author":"CV Oddis","year":"2018","unstructured":"Oddis, C. V. & Aggarwal, R. Treatment of myositis. Nat. Rev. Rheumatol. 14, 279\u2013289 (2018).","journal-title":"Nat. Rev. Rheumatol."},{"key":"1001_CR122","doi-asserted-by":"publisher","first-page":"504","DOI":"10.1038\/s41571-020-0352-8","volume":"17","author":"K Esfahani","year":"2020","unstructured":"Esfahani, K. et al. Moving towards personalized treatments of immune-related adverse events. Nat. Rev. Clin. Oncol. 17, 504\u2013515 (2020).","journal-title":"Nat. Rev. Clin. Oncol."},{"key":"1001_CR123","doi-asserted-by":"publisher","first-page":"57","DOI":"10.1111\/imr.12614","volume":"281","author":"A Mantovani","year":"2018","unstructured":"Mantovani, A., Barajon, I. & Garlanda, C. IL\u20101 and IL\u20101 regulatory pathways in cancer progression and therapy. Immunol. Rev. 281, 57\u201361 (2018).","journal-title":"Immunol. Rev."},{"key":"1001_CR124","doi-asserted-by":"publisher","first-page":"860","DOI":"10.1158\/2326-6066.CIR-18-0682","volume":"7","author":"D Johnson","year":"2019","unstructured":"Johnson, D. et al. IL17A blockade successfully treated psoriasiform dermatologic toxicity from immunotherapy. Cancer Immunol. Res. 7, 860\u2013865 (2019).","journal-title":"Cancer Immunol. Res."},{"key":"1001_CR125","doi-asserted-by":"publisher","first-page":"1989","DOI":"10.1056\/NEJMc1703047","volume":"376","author":"K Esfahani","year":"2017","unstructured":"Esfahani, K. & Miller, W. H. Reversal of autoimmune toxicity and loss of tumor response by interleukin-17 blockade. N. Engl. J. Med. 376, 1989\u20131991 (2017).","journal-title":"N. Engl. J. Med."},{"key":"1001_CR126","doi-asserted-by":"publisher","first-page":"2377","DOI":"10.1056\/NEJMc1901677","volume":"380","author":"J-E Salem","year":"2019","unstructured":"Salem, J.-E. et al. Abatacept for severe immune checkpoint inhibitor-associated myocarditis. N. Engl. J. Med. 380, 2377\u20132379 (2019).","journal-title":"N. Engl. J. Med."},{"key":"1001_CR127","doi-asserted-by":"publisher","first-page":"614","DOI":"10.1158\/2159-8290.CD-20-0856","volume":"11","author":"SC Wei","year":"2021","unstructured":"Wei, S. C. et al. A genetic mouse model recapitulates immune checkpoint inhibitor-associated myocarditis and supports a mechanism-based therapeutic intervention. Cancer Discov. 11, 614\u2013625 (2021).","journal-title":"Cancer Discov."},{"key":"1001_CR128","doi-asserted-by":"publisher","first-page":"273","DOI":"10.1111\/j.1600-065X.2008.00754.x","volume":"228","author":"K Ghoreschi","year":"2009","unstructured":"Ghoreschi, K., Laurence, A. & O\u2019Shea, J. J. Janus kinases in immune cell signaling. Immunol. Rev. 228, 273\u2013287 (2009).","journal-title":"Immunol. Rev."},{"key":"1001_CR129","doi-asserted-by":"publisher","first-page":"1768","DOI":"10.1056\/NEJMoa2109927","volume":"386","author":"SR Ytterberg","year":"2022","unstructured":"Ytterberg, S. R., Bhatt, D. L. & Connell, C. A. Cardiovascular and cancer risk with tofacitinib in rheumatoid arthritis. N. Engl. J. Med. 386, 1768 (2022).","journal-title":"N. Engl. J. Med."},{"key":"1001_CR130","first-page":"0846","volume":"11","author":"J Zak","year":"2023","unstructured":"Zak, J. et al. Myeloid reprogramming by JAK inhibition enhances checkpoint blockade therapy. J. Immunother. Cancer 11, 0846 (2023).","journal-title":"J. Immunother. Cancer"},{"key":"1001_CR131","doi-asserted-by":"publisher","first-page":"933","DOI":"10.1016\/S0140-6736(18)30533-6","volume":"391","author":"JJ Moslehi","year":"2018","unstructured":"Moslehi, J. J., Salem, J.-E., Sosman, J. A., Lebrun-Vignes, B. & Johnson, D. B. Increased reporting of fatal immune checkpoint inhibitor-associated myocarditis. Lancet 391, 933 (2018).","journal-title":"Lancet"},{"key":"1001_CR132","doi-asserted-by":"publisher","DOI":"10.1186\/s12974-020-01847-9","volume":"17","author":"W Gilmore","year":"2020","unstructured":"Gilmore, W. et al. Repopulation of T, B, and NK cells following alemtuzumab treatment in relapsing-remitting multiple sclerosis. J. Neuroinflammation 17, 189 (2020).","journal-title":"J. Neuroinflammation"},{"key":"1001_CR133","first-page":"689","volume":"25","author":"JD Bowen","year":"2019","unstructured":"Bowen, J. D. Highly aggressive multiple sclerosis. Continuum 25, 689\u2013714 (2019).","journal-title":"Continuum"},{"key":"1001_CR134","doi-asserted-by":"publisher","first-page":"2375","DOI":"10.1056\/NEJMc1903064","volume":"380","author":"K Esfahani","year":"2019","unstructured":"Esfahani, K. et al. Alemtuzumab for immune-related myocarditis due to PD-1 therapy. N. Engl. J. Med. 380, 2375\u20132376 (2019).","journal-title":"N. Engl. J. Med."},{"key":"1001_CR135","doi-asserted-by":"publisher","first-page":"3103","DOI":"10.1111\/ajt.12514","volume":"13","author":"I Popow","year":"2013","unstructured":"Popow, I. et al. A comprehensive and quantitative analysis of the major specificities in rabbit antithymocyte globulin preparations. Am. J. Transpl. 13, 3103\u20133113 (2013).","journal-title":"Am. J. Transpl."},{"key":"1001_CR136","doi-asserted-by":"publisher","first-page":"921","DOI":"10.1038\/bjc.2017.253","volume":"117","author":"RY Tay","year":"2017","unstructured":"Tay, R. Y. et al. Successful use of equine anti-thymocyte globulin (ATGAM) for fulminant myocarditis secondary to nivolumab therapy. Br. J. Cancer 117, 921\u2013924 (2017).","journal-title":"Br. J. Cancer"},{"key":"1001_CR137","doi-asserted-by":"publisher","first-page":"314","DOI":"10.1002\/art.37754","volume":"65","author":"CV Oddis","year":"2013","unstructured":"Oddis, C. V. et al. Rituximab in the treatment of refractory adult and juvenile dermatomyositis and adult polymyositis: a randomized, placebo\u2010phase trial. Arthritis Rheum. 65, 314\u2013324 (2013).","journal-title":"Arthritis Rheum."},{"key":"1001_CR138","doi-asserted-by":"publisher","first-page":"25","DOI":"10.2147\/ITT.S377056","volume":"12","author":"SS Nair","year":"2023","unstructured":"Nair, S. S. & Jacob, S. Novel immunotherapies for myasthenia gravis. Immunotargets Ther. 12, 25\u201345 (2023).","journal-title":"Immunotargets Ther."},{"key":"1001_CR139","doi-asserted-by":"publisher","first-page":"212","DOI":"10.1002\/mus.27326","volume":"64","author":"U Usman","year":"2021","unstructured":"Usman, U. et al. The use of eculizumab in ventilator\u2010dependent myasthenia gravis patients. Muscle Nerve 64, 212\u2013215 (2021).","journal-title":"Muscle Nerve"},{"key":"1001_CR140","doi-asserted-by":"publisher","DOI":"10.1212\/NXI.0000000000200177","volume":"11","author":"C Nelke","year":"2024","unstructured":"Nelke, C. et al. Immune checkpoint inhibition-related myasthenia\u2013myositis\u2013myocarditis responsive to complement blockade. Neurol. Neuroimmunol. Neuroinflamm 11, e200177 (2024).","journal-title":"Neurol. Neuroimmunol. Neuroinflamm"},{"key":"1001_CR141","doi-asserted-by":"publisher","first-page":"368","DOI":"10.1002\/mus.28037","volume":"69","author":"S Zadeh","year":"2024","unstructured":"Zadeh, S. et al. Novel uses of complement inhibitors in myasthenia gravis\u2014two case reports. Muscle Nerve 69, 368\u2013372 (2024).","journal-title":"Muscle Nerve"},{"key":"1001_CR142","doi-asserted-by":"publisher","first-page":"3052","DOI":"10.3389\/fimmu.2019.03052","volume":"10","author":"KL Gable","year":"2020","unstructured":"Gable, K. L. & Guptill, J. T. Antagonism of the neonatal Fc receptor as an emerging treatment for myasthenia gravis. Front. Immunol. 10, 3052 (2020).","journal-title":"Front. Immunol."},{"key":"1001_CR143","doi-asserted-by":"publisher","first-page":"526","DOI":"10.1016\/S1474-4422(21)00159-9","volume":"20","author":"J Howard James F","year":"2021","unstructured":"Howard James F, J. et al. Safety, efficacy, and tolerability of efgartigimod in patients with generalised myasthenia gravis (ADAPT): a multicentre, randomised, placebo-controlled, phase 3 trial. Lancet Neurol. 20, 526 (2021).","journal-title":"Lancet Neurol."},{"key":"1001_CR144","doi-asserted-by":"publisher","first-page":"383","DOI":"10.1016\/S1474-4422(23)00077-7","volume":"22","author":"J Grosskreutz","year":"2023","unstructured":"Grosskreutz, J. et al. Safety and efficacy of rozanolixizumab in patients with generalised myasthenia gravis (MycarinG): a randomised, double-blind, placebo-controlled, adaptive phase 3 study. Lancet Neurol. 22, 383\u2013394 (2023).","journal-title":"Lancet Neurol."},{"key":"1001_CR145","doi-asserted-by":"publisher","first-page":"P1-8.006","DOI":"10.1212\/WNL.0000000000202470","volume":"100","author":"M Campbell","year":"2023","unstructured":"Campbell, M. et al. Efgartigimod for pembrolizumab-induced myasthenia gravis refractory to standard therapy. Neurology 100, P1-8.006 (2023).","journal-title":"Neurology"},{"key":"1001_CR146","doi-asserted-by":"publisher","first-page":"9012","DOI":"10.1200\/JCO.2017.35.15_suppl.9012","volume":"35","author":"FC Santini","year":"2017","unstructured":"Santini, F. C. et al. Safety of retreatment with immunotherapy after immune-related toxicity in patients with lung cancers treated with anti-PD(L)-1 therapy. J. Clin. Oncol. 35, 9012 (2017).","journal-title":"J. Clin. Oncol."},{"key":"1001_CR147","doi-asserted-by":"publisher","first-page":"250","DOI":"10.1093\/annonc\/mdx642","volume":"29","author":"MH Pollack","year":"2018","unstructured":"Pollack, M. H. et al. Safety of resuming anti-PD-1 in patients with immune-related adverse events (irAEs) during combined anti-CTLA-4 and anti-PD1 in metastatic melanoma. Ann. Oncol. 29, 250\u2013255 (2018).","journal-title":"Ann. Oncol."},{"key":"1001_CR148","first-page":"982","volume":"156","author":"A Brunot","year":"2020","unstructured":"Brunot, A. et al. Association of anti\u2013programmed cell death 1 antibody treatment with risk of recurrence of toxic effects after immune-related adverse events of ipilimumab in patients with metastatic melanoma. Arch. Dermatol. 156, 982\u2013986 (2020).","journal-title":"Arch. Dermatol."},{"key":"1001_CR149","doi-asserted-by":"publisher","first-page":"1310","DOI":"10.1001\/jamaoncol.2019.1022","volume":"5","author":"A Simonaggio","year":"2019","unstructured":"Simonaggio, A. et al. Evaluation of readministration of immune checkpoint inhibitors after immune-related adverse events in patients with cancer. JAMA Oncol. 5, 1310\u20131317 (2019).","journal-title":"JAMA Oncol."},{"key":"1001_CR150","doi-asserted-by":"publisher","first-page":"226","DOI":"10.1186\/s40425-019-0711-0","volume":"7","author":"YR Badran","year":"2019","unstructured":"Badran, Y. R. et al. Concurrent therapy with immune checkpoint inhibitors and TNF\u03b1 blockade in patients with gastrointestinal immune-related adverse events. J. Immunother. Cancer 7, 226 (2019).","journal-title":"J. Immunother. Cancer"},{"key":"1001_CR151","doi-asserted-by":"publisher","first-page":"1328","DOI":"10.1126\/science.abb9847","volume":"370","author":"S Krishna","year":"2020","unstructured":"Krishna, S. et al. Stem-like CD8 T cells mediate response of adoptive cell immunotherapy against human cancer. Science 370, 1328\u20131334 (2020).","journal-title":"Science"},{"key":"1001_CR152","doi-asserted-by":"publisher","DOI":"10.1073\/pnas.2116277119","volume":"119","author":"X-ZJ Guo","year":"2022","unstructured":"Guo, X.-Z. J. & Elledge, S. J. V-CARMA: a tool for the detection and modification of antigen-specific T cells. Proc. Natl Acad. Sci. USA 119, e2116277119 (2022).","journal-title":"Proc. Natl Acad. Sci. USA"}],"container-title":["Nature Reviews Neurology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41582-024-01001-6.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41582-024-01001-6","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41582-024-01001-6.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,9,2]],"date-time":"2024-09-02T09:25:36Z","timestamp":1725269136000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41582-024-01001-6"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,8,9]]},"references-count":152,"journal-issue":{"issue":"9","published-print":{"date-parts":[[2024,9]]}},"alternative-id":["1001"],"URL":"https:\/\/doi.org\/10.1038\/s41582-024-01001-6","relation":{},"ISSN":["1759-4758","1759-4766"],"issn-type":[{"value":"1759-4758","type":"print"},{"value":"1759-4766","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,8,9]]},"assertion":[{"value":"11 July 2024","order":1,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"9 August 2024","order":2,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"A.C.G. declares that she has acted as a consultant and\/or medical advisory board member for Argenx, Alexion and UCB (Ra Pharma); receives publishing royalties from Oakstone Publications; and has received research funding from the MGNet Rare Disease Network, MGNet Scholar Award, National Institutes of Health (NIH) Rare Disease Clinical and Research Training Program, Project Data Sphere, Dysimmune Disease Foundation and National Institute of Neurological Disorders and Stroke (NINDS) with Biosensics (grant 1R44NS122672-01A1). M.O\u2019H. declares no competing interests.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}]}}